ALDH3A1 and peripheral neuropathy: Among patients carrying the GC+CC genotype of the ALDH3A1 gene, peripheral neuropathy severity significantly increased after cycle two, skin toxicity severity increased after cycle one, and alopecia severity increased after all chemotherapy cycles compared to baseline (p-value < 0.05) (Table 16).